WO2003002119A1 - Treatment and prevention of lipodermatosclerosis - Google Patents

Treatment and prevention of lipodermatosclerosis Download PDF

Info

Publication number
WO2003002119A1
WO2003002119A1 PCT/GB2002/002955 GB0202955W WO03002119A1 WO 2003002119 A1 WO2003002119 A1 WO 2003002119A1 GB 0202955 W GB0202955 W GB 0202955W WO 03002119 A1 WO03002119 A1 WO 03002119A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
pyridyl
chelating agent
use according
group
Prior art date
Application number
PCT/GB2002/002955
Other languages
French (fr)
Inventor
Sarah Elizabeth Herrick
Geoffrey John Laurent
Original Assignee
Johnson & Johnson Medical Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson Medical Limited filed Critical Johnson & Johnson Medical Limited
Publication of WO2003002119A1 publication Critical patent/WO2003002119A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Definitions

  • the present invention relates to the use of iron scavenging compounds for the preparation of compositions for use in the treatment and prevention of lipodermatosclerosis.
  • venous disease In the United Kingdom, 10-20% of the adult population is affected by the complications of venous disease, including deep vein thrombosis, varicose veins, lipodermatosclerosis and venous ulceration. Approximately 50% of all venous ulcers are present for periods greater than nine months and two-thirds are recurrent. Venous problems are not only limited to the elderly, since greater than 40% of patients form venous ulcers before the age of 50. Venous disease consumes approximately 2% of the total annual healthcare budget in the UK.
  • venous hypertension In patients with venous disease, the valves in the veins of the lower limb become incompetent, generally due to deep vein thrombosis and/or superficial vein incompetence, resulting in venous hypertension on exercise and the retrograde flow of blood through the superficial venous system (venous reflux) to the blood vessels in the skin.
  • Chronic venous disease often progresses from defective valves and the appearance of varicose veins, to the development of skin changes in the lower leg and finally to the formation of venous ulcers.
  • venous disease Despite the frequency of venous disease, surprisingly little is understood of the mechanisms by which chronic venous hypertension leads to venous ulceration.
  • LDS lipodermatosclerosis
  • LDS skin is characterised by skin induration or thickening and brown pigmentation caused by haemosiderin deposition. These features often occur in skin before ulceration as well as in skin surrounding an ulcer. The degree of skin thickening (induration or fibrosis) is thought to be directly related to venous ulcer formation and subsequently delayed healing.
  • the present invention relates to the inhibition of the effects of excess iron deposition in the skin following chronic venous insufficiency.
  • the present inventors have found that excess iron may have a much larger influence on the early stages of lipodermatosclerosis than previously thought.
  • Ackerman et al. performed x-ray spectrometry, a method based on x-ray fluorescence analysis, for non-invasive determination of iron levels in the skin of sixteen patients with venous ulceration.
  • the mean ( ⁇ SEM) iron concentration in the skin around the venous ulcer was elevated, compared with control values of nonulcerated skin (250 ⁇ 54 vs 128 ⁇ 39 ⁇ g) and compared with normal skin from the forearm (250 ⁇ 54 vs 14 ⁇ 2.5 ⁇ g).
  • This group suggested that dermal iron deposition may not be an incidental by-product of increased venous pressure, but may actively perpetuate tissue damage in venous ulcerations.
  • attempts to treat venous ulcers with inhibitors of the effects of excess iron have not been overly effective.
  • the present inventors have found that there is little evidence of haemosiderin deposition in ulcer base tissue. It is thought that elevated levels of iron in ulcer wound fluid may be due to iron leaching into the wound fluid, father than to iron accumulation in the ulcer tissue itself
  • the present invention provides the use of an iron chelating agent for the preparation of a composition for use in the prevention of lipodermatosclerosis by topical application to the lower leg.
  • the present invention provides the use of an iron chelating agent for the preparation of a composition for use in the treatment of lipodermatosclerosis by topical application to the lower leg.
  • chelating agent refers to a chemical moiety that functions as a bidentate or multidentate ligand for dissolved iron. Chelating agents which may be used herein should be safe for topical application and should exhibit a sufficiently high binding coefficient with dissolved iron to lower the concentration of dissolved iron in vivo and should neutralise the fibrotic effect of the iron when the iron is bound thereto. The chelating agent should also be capable of penetrating into the skin following topical application. By “safe” is meant chelating agents which may be used topically, at typical usage levels for extended periods of time, without causing any significant adverse skin reactions or other side effects.
  • the chelating agents useful in the present invention may be classified according to their donor groups; see The Design and Synthesis of Chelating Agents", Development of Iron Chelators for Clinical Use, Martell, Anderson and Badman, eds., Elsevier North Holland, Inc., New York, N.Y. (1981), pp. 67-104, which is hereby incorporated by reference. Because some chelating agents have more than one type of donor group, they may fall into more than one of the classes defined in this reference.
  • the chelating agent is selected from the group consisting of aromatic amines, carbonyls, oximates, amines, carboxylates, alkoxides, enolates, phenoxides, catecholates, hydroxy acids, hydroxamates, ketoenolates, mercaptides, hydroxy aromatic amines, aromatic hydroxy acids, and mixtures thereof
  • the chelating agent is selected from the group consisting of aromatic amines, carbonyls, oximates, enolates, phenoxides, catecholates and hydroxylates, and mixtures thereof.
  • Aromatic amine chelating agents preferably are selected from the group consisting of: 2,2'-dipyridylamine; 1 ,10-phenanthroline ⁇ o-phenanthroline ⁇ ; di-2-pyridyl ketone; 2,3-bis(2-pyridyl) pyrazine; 2,3-bis(2-pyridyl)-5,6-dihydropyrazine; 1 ,1 '- carbonyldiimidazole; 2,4-bis(5,6-diphenyl-1 ,2,4-triazine-3-yl)pyridine; 2,4,6-tri(2- pyridyl)-1 ,3,5-triazine; 4,4'-dimethyl-2,2'-dipyridyl; 2,2'-biquinoline; di-2-pyridyl glyoxal ⁇ 2,2'-pyridil ⁇ ; 2-(2-pyridyl)benzimidazole; 2,2'-bipyrazine
  • aromatic amine chelating agent is selected from the group consisting of: di-2-pyridyl ketone; 1 ,1 '-carbonyldiimidazole and 2,2'-pyridil.
  • Oximate chelating agents preferably are selected from the group consisting of: 2- furildioxime; phenyl 2-pyridyl ketoxime; and 1 ,2-cyclohexanedione dioxime.
  • the chelating agent is selected from the group consisting of: ethylenediamine-N,N-bis-(2-hydroxyphenylacetic acid) dimethyl ester; diethyldithiocarbamic acid; 1-pyrrolidinecarbodithioic acid; and 3-amino-5,6- dimethyl-1 ,2,4-triazine.
  • Carboxy chelating agents preferably are selected from the group consisting of: 2,3-dihydroxybenzoic acid; 3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridine- carboxylic acid ⁇ pyridoxic acid ⁇ ; ethylenediamine-N,N-bis-(2-hydroxyphenylacetic acid) dimethyl ester; and 2,6-pyridinedicarboxylic acid.
  • the chelating agent is selected from the group consisting of: 5-hydroxy-2-(hydroxymethyl)-4H-pyran-4-one ⁇ kojic acid ⁇ and pyridoxic acid.
  • the chelating agent is selected from the group consisting of: 1 ,2-dimethyl-3-hydroxypyrid-4-one; 3-hydroxy-2-methyl-4-pyrone; kojic acid; 1-hydroxy-4-methyl-6-(2,4,4-trimethylpentyl)-2(1H)-pyridone ⁇ piroctone olamine-Octopirox ⁇ ; and 6-cyclohexyI-1 -hydroxy-4-methyl-2(1 H)-pyridinone ⁇ Ciclopirox ⁇ .
  • the chelating agent is selected from the group consisting of: Octopirox; 6-hydroxy-2-phenyl-3(2H)-pyridazinone; Ciclopirox; 2,3- dihydroxybenzoic acid; 4,5-dihydroxy-1,3-benzene-disulfonic acid ⁇ Tiron ⁇ ; ethylenediamine-N,N-bis-(2-hydroxyphenylacetic acid) dimethyl ester; pyridoxic acid; 2,3-dihydroxypyridine; 2,4,5-trihydroxypyrimidine; and 2,3- dihydroxynaphthalene.
  • the chelating agent is selected from the group consisting of: 2,3-dihydroxynaphthalene; 2,4,5-trihydroxypyrimidine; kojic acid; 2,3- dihydroxypyridine; 3-hydroxy-2-methyl-4-pyrone; Tiron; 2,3-dihydroxybenzoic acid; 4-(2-amino-1-hydroxyethyl)-1 ,2-benzenediol; Ciclopirox; and Octopirox.
  • the chelating agent is selected from the group consisting of: 2,3-dihydroxybenzoic acid; and pyridoxic acid.
  • the chelating agent is selected from the group consisting of: N-benzoyl -N-phenyl-hydroxylamine; desferrioxamine B ⁇ Desferal ⁇ ; Ciclopirox; and Octopirox.
  • the chelating agent is selected from the group consisting of: kojic acid.
  • the chelating agent is selected from the group consisting of: diethyldithiocarbamic acid; and 1-pyrrolidinecarbodithioic acid.
  • Preferred chelating agents useful in the present invention which fall within the class of hydroxy aromatic amines include the following: 5,7-dichloro-8- hydroxyquinoline.
  • the chelating agent is selected from the group consisting of: 2,3-dihydroxybenzoic acid; pyridoxic acid; and 2,6- pyridinedicarboxylic acid.
  • the chelating agent is selected from the group consisting of: 2,2'-dipyridylamine; o-phenanthroline; di-2-pyridyl ketone; 2- furildioxime; 2,3-bis(2-pyridyl) pyrazine; Octopirox; 2,3-dihydroxybenzoic acid; ethylenediamine-N,N-bis-(2-hydroxyphenylacetic acid), dimethyl ester; 1,1'- carbonyldiimidazole; 1 ,2-dimethyl-3-hydroxypyrid-4-one; 2,4,6-tri(2-pyridyl)-1 ,3,5- triazine; 1-pyrrolidinecarbodithioic acid; diethyldithiocarbamic acid; Ciclopirox; 2,2'- dipyridyl; 1 ,2-cyclohexanedione dioxime; 3-hydroxy-2-methyl-4-pyrone; 2,3-bis(2- pyridyl)-5,
  • the chelating agent is selected from the group consisting of: 2,2'-dipyridylamine; o-phenanthroline, di-2-pyridyl ketone; 2- furildioxime; 2,3-bis(2-pyridyl) pyrazine; Octopirox; 2,3-dihydroxybenzoic acid; ethylenediamine-N,N-bis-(2-hydroxyphenylacetic acid), dimethyl ester; 1 ,1'- carbonyldiimidazole; 1 ,2-dimethyl-3-hydroxypyrid-4-one; 2,4,6-tri(2-pyridyl)-1 ,3,5- triazine; 1-pyrrolidinecarbodithioic acid; diethyldithiocarbamic acid; and Ciclopirox.
  • More preferred still chelating agents for use in the compositions and methods of the present invention including the following: 2,2'-dipyridylamine; o-phenanthroline, di-2-pyridyl ketone; 2-furildioxime; 2,3-bis(2-pyridyl) pyrazine; Octopirox; 2,3- dihydroxybenzoic acid; and ethylenediamine-N,N-bis-(2-hydroxyphenylacetic acid), dimethyl ester.
  • the chelating agent is selected from the group consisting of: 2,2'-dipyridylamine; o-phenanthroline; di-2-pyridyl ketone; and 2- furildioxime.
  • the chelating agent has a binding coefficient with aqueous Fe 3+ of at least 10 6 , preferably at least 10 9 and more preferably at least 10 12 .
  • the binding coefficient is defined as the equilibrium constant for the reaction Fe 3+ + L n' ⁇ FeL (3 - n)+
  • the chelating agent is present in the composition at a concentration by weight of from about 1% to about 10%, preferably from about 2% to about 5%, of the composition.
  • the preferred chelating agents listed hereinabove are generally commercially available from one or more of the following suppliers: Aldrich Chemical Company, Milwaukee, Wis.; G.F.S. Chemicals, Columbus, Ohio; Dojindo Laboratories, Kumamoto, Japan; Sigma Chemical Company, St. Louis, Mo.; Ciba-Geigy, Summit, N.J.; Strem Chemicals, Newburyport, Mass.; and American Hoechst Corp., Summerville, N.J.
  • a method for synthesizing 1 ,2-dimethyl-3-hydroxypyrid-4- one is disclosed in Kontoghiorghes, G. J., "L1--1 ,2-dimethyl-3-hydroxypyrid-4- one", Drugs of the Future, Vol. 13, No. 5 (1988), pp. 413-415, which is hereby incorporated by reference.
  • compositions used in the present invention contain a safe and effective amount of an acceptable carrier.
  • acceptable topical carrier encompasses both pharmaceutically-acceptable carriers and cosmetically-acceptable carriers, and it encompasses substantially nonirritating compatible components (either taken alone or in mixtures) which are suitable for delivering the active component to the skin.
  • compatible means that the components of the carrier must be capable of being commingled with the chelating agent, and with each other, in a manner such that there is no interaction which would substantially reduce the efficacy of the composition during use for protecting the skin from the effects of UV radiation.
  • carrier must, of course, be of sufficiently high purity and sufficiently low toxicity to render them suitable for chronic topical administration to the skin of humans or lower animals.
  • safe and effective amount of carrier means an amount sufficient to deliver the chelating agent to the skin but not so much as to cause any side effects or skin reactions, generally from about 50% to about 99%, preferably from about 90% to about 98%, of the composition.
  • composition made in the present invention may be of any conventional topical application type. These include, for example, lotions, creams, gels, sticks, sprays, ointments, pastes, mousses and cosmetics. These product types may comprise either of two basic types of carrier systems, i.e., solutions and emulsions.
  • the compositions formulated as solutions typically include a pharmaceutically- or cosmetically-acceptable organic solvent. The most typical example of such a solvent is water.
  • organic solvents examples include: propylene glycol, polyethylene glycol (200-600), polypropylene glycol (425-2025), glycerol, 1 ,2,4-butanetriol, sorbitol esters, 1 ,2,6-hexanetriol, ethanol, isopropanol, butanediol, and mixtures thereof.
  • These solutions contain from about 1% to about 20%, preferably from about 2% to about 10%, of the chelating agent, and from about 80% to about 99%, preferably from about 90% to about 98%, of an acceptable organic solvent.
  • Emollients may be included in the carrier system of the present invention formulated as a solution.
  • compositions contain from about 1% to about 20% of the chelating agent and from about 2% to about 50% of a pharmaceutically/cosmetically-acceptable emollient.
  • emollients refer to materials used for the prevention or relief of dryness, as well as for the protection of the skin.
  • suitable emollients are known and may be used herein. Sagatin, Cosmetics, Science and Technology, 2nd Edition, Vol. 1 , pp. 32-43 (1972), incorporated herein by reference, contains numerous examples of suitable materials.
  • Lotions typically comprise from about 1 % to about 20%, preferably from about 2% to about 10%, of the chelating agent; from about 1% to about 20%, preferably from about 5% to about 10%, of an emollient; and from about 50% to about 90%, preferably from about 60% to about 80%, water.
  • Another type of product that may be formulated from a solution carrier system is a cream.
  • a cream of the present invention would comprise from about 1% to about 20%, preferably from about 2% to about 10%, of the chelating agent; from about 5% to about 50%, preferably from about 10% to about 20%, of an emollient, and from about 45% to about 85%, preferably from about 50% to about 75%, water.
  • An ointment may comprise a simple base of animal or vegetable oils or semi-solid hydrocarbons (oleaginous). Ointments may also comprise absorption ointment bases which absorb water to form emulsions. Examples of such ointment bases include, anhydrous lanolin and hydrophilic petrolatum. Emulsion ointment bases may be oil-in-water or water-in-oil emulsions. Ointment carriers may also be water soluble. Examples of such ointment carriers include glycol ethers, propylene glycols, polyoxyl stearates, and polysorbates.
  • An ointment may also comprise from about 2% to about 10% of an emollient plus from about 0.1% to about 2% of a thickening agent.
  • suitable thickening agents include: cellulose derivatives (e.g., methyl cellulose and hydroxy propylmethyl cellulose), synthetic high molecular weight polymers (e.g., carboxyvinyl polymer and polyvinyl alcohol), plant hydrocolloids (e.g., karaya gum and tragacanth gum), clay thickeners (e.g., colloidal magnesium aliminum silicate and bentonite), and carboxyvinyl polymers (Carbopols®)
  • the carrier is formulated as an emulsion, from about 1% to about 10%, preferably from about 2% to about 5%, of the carrier system comprises an emulsifier.
  • Emulsifiers may be nonionic, anionic or cationic.
  • Preferred emulsifiers are anionic or nonionic, although the other types may also be used.
  • Single emulsion skin care preparations, such as lotions and creams, of the oil-in- water type and water-in-oil type are well-known in the cosmetic art and are useful in the present invention.
  • Lotions and creams can be formulated as emulsions as well as solutions.
  • Such lotions comprise from about 1 % to about 20%, preferably from about 2% to about 10%, of the chelating agent; from about 1% to about 20%, preferably from about 5% to about 10%, of an emollient; from about 25% to about 75%, preferably from about 45% to about 95%, water; and from about 1% to about 10%, preferably from about 2% to about 5%, of an emulsifier.
  • Such creams would typically comprise from about 1% to about 20%, preferably from about 2% to about 10%, of the chelating agent; from about 1% to about 20%, preferably from about 5% to about 10%, of an emollient; from about 20% to about 80%, preferably from about 30% to about 70%, water; and from about 1% to about 10%, preferably from about 2% to about 5%, of an emulsifier.
  • a suitable amount of a thickening agent is added to a cream or lotion formulation.
  • the compositions may also be formulated as makeup products such as foundations, thereby enabling the compositions also to cover up the discoloration symptoms of lipodermatosclerosis. Foundations are solution or lotion-based with appropriate amounts of thickeners, pigments and fragrance.
  • compositions may also include a safe and effective amount of a penetration enhancing agent.
  • safe and effective amount is meant an amount sufficient to enhance penetration of the chelating agent into the skin but not so much as to cause any side effects or skin reactions, generally from about 1% to about 5% of the composition.
  • useful penetration enhancers are disclosed in US-A-4,537,776, US-A-4,552,872, US-A-4,557,934, US-A-4,130,667, US-A-3,989,816, US-A-4,017,641 , EP-A-0043738, US-A-4,537,776, US-A- 4,557,934 and US-A-4,130,667.
  • compositions may comprise, in addition to the chelating agent, a safe and effective amount of a radical scavenging compound.
  • safe and effective amount is meant an amount sufficient to inhibit the deleterious effects of iron catalysed free radical formation when the composition is properly applied, but not so much as to cause any side effects or adverse skin reactions.
  • the use of the radical scavenger tocopherol sorbate in the present invention in combination with the chelating agent is preferred. From about 1% to about 5% of these radical scavenging compounds may generally be used in the present invention in combination with the levels of chelating agent taught herein. Exact amounts will vary depending on which particular compound is used as these compounds vary somewhat in potency.
  • the treatment or prevention comprises daily topical application for a period of at least three weeks.
  • the patient is suffering from a venous disease or venous insufficiency.
  • a venous disease or venous insufficiency Preferably this is still at an early stage, for example the patient may have varicose veins but still little or no LDS.
  • a safe and effective amount is from about 0.001 mg to about 1.0 mg, preferably from about 0.01 mg to about 0.5 mg, more preferably from about 0.05 mg to about 0.1 mg of the chelating agent per cm 2 skin.
  • the chelating agent may be simply spread or sprayed onto the skin or may preferably be rubbed into the skin to enhance penetration.
  • application of the chelating agent several times daily; generally from about 2 times to about 5 times, preferably 2 times daily is preferred.
  • application of the chelating agent is continued daily for as long as the underlying venous insufficiency persists.
  • the current study addressed the hypothesis that excess iron deposited in skin subjected to chronic venous insufficiency is phagocytosed by dermal cells and at low levels causes enhanced collagen deposition leading to fibrotic skin changes but when in excess it mediates cell death and subsequent ulceration.
  • the initial aims of the study were to assess the level and distribution of iron in the lower leg skin of patients with progressive venous disease. Histological and ultrastructural analysis of LDS skin biopsies showed that dermal fibroblasts as well as inflammatory cells contained iron in the form of ferritin and haemosiderin. The effects of increasing levels of iron on dermal fibroblast collagen production and cell viability were determined in vitro. Results suggest that iron at low concentrations causes increased collagen production but higher concentrations induces a significant decrease in cell viability which is likely to be due to iron induced apoptosis.
  • Inflammatory cells including as macrophages, mast cells, neutrophils and lymphocytes, were identified by indirect immunocytochemistry. Sections were dewaxed, rehydrated, and treated with 0.3% H 2 0 2 in PBS for 20min to block endogenous peroxidase activity followed by blocking serum corresponding the host of the secondary antibody. Sections were incubated with well-characterised primary antibodies for 1hr at room temperature in a humidified chamber.
  • Monoclonal primary antibodies were raised against human macrophage, CD68 (1 :100 dilution; Dako, Cambridge, UK), neutrophil, CD15s (1:50 dilution; Serotec Ltd, Oxford, UK), mast cell tryptase (1 : 100 dilution; Serotec Ltd, Oxford, UK) and T-lymphocyte, CD3 (1:50 dilution, Serotec Ltd, Oxford, UK). Following three washes with PBS, the sections were incubated with biotinyiated-conjugated secondary antisera against mouse or rat IgG (1 :300 dilution; Dako, Cambridge, UK), for 1hr at room temperature.
  • Sections were washed three times with PBS prior to incubation with streptavidin-conjugated horseradish peroxidase (1:100 dilution; Dako, Cambridge, UK) for 30min. Peroxidase activity was visualised with chromogen diaminobenzidine substrate (FAST DAB, Sigma, Poole, UK) and sections were counterstained with 1% eosin and mounted. Control sections were incubated with either normal blocking serum or mouse/rat lgG1 instead of primary antisera. For dual localisation, sections were initially assessed for inflammatory cells by immunoperoxidation and counterstained with Perls' Prussian blue for haemosiderin.
  • haemosiderin was deposited throughout the dermis, in both a cellular and extracellular distribution. In addition, it was clearly found in the few remaining septal cells of the fibrotic subcutaneous layer. Dual localisation of inflammatory cells and haemosiderin demonstrated that macrophages, mast cells and neutrophils contained iron deposits.
  • Human dermal fibroblasts were isolated from normal dermal skin by explant culture and were grown in DMEM medium supplemented with penicillin (100U/ml), streptomycin (100 ⁇ g/ml) and L-glutamine (2mM), containing 10% FCS at 37DC, in a humidified, 5% C0 2 atmosphere. Cells were characterised using well- characterised antibodies against specific markers and were used at passage 7 to 9.
  • Fibroblast viability assay Primary dermal fibroblasts were plated in 96-well plates at 10 5 cells/ ml in 100 ⁇ l media supplemented with 0.4% FCS. Intact cells are relatively impermeable to iron therefore iron was loaded using the iron-chelating fungistat 8-hydroxyquinoline
  • 8HQ chelates with iron and rapidly transfers the metal across the intact plasma membrane of cells. After 24 hrs, cells were washed twice with PBS and loaded with 100 ⁇ l serum-free DMEM containing stoichiometric quantities of ferric chloride and ferric ammonium citrate (to prevent precipitation of insoluble iron hydroxides) with 8-hydroxyquinonine (8-HQ) used as a carrier at concentrations of 1-100 ⁇ M in a method modified from Jacob AK, Hotchkiss RS, DeMeester SL, Hiramatsu M, Karl IE, Swanson PE, Cobb JP, Buchman TG. Surgery 122:243-53 (1997). Control experiments added iron without 8-HQ carrier and 8-HQ without iron.
  • the membrane-impermeable iron chelator, deferoxamine (DFX; Sigma) at 200 ⁇ M was added to prevent the uptake of iron by the cells.
  • DFX deferoxamine
  • Previous studies have shown that iron loading is complete after 30min (Jacob et al., 1997), therefore 30 min incubation with iron was used in all experiments.
  • Viable cells accumulate the vital dye, neutral red, in their lysosomes and so neutral red (0.003%) in 100 ⁇ l serum-free media was applied to washed cells and incubated for a further 2 hr. Excess dye was aspirated, the cells were washed with phosphate buffered saline, pH 7.4 (PBS), and lysed with 100 ⁇ l 50% ethanol containing 1% acetic acid. Absorbency was measured at 560nm and viability calculated as a fraction of control cell absorbency after blank absorbency was deducted.
  • PBS phosphate buffered saline
  • TUNEL assay for apoptosis was used.
  • cells were grown on glass Labtek slides and when semi-confluent rinsed with PBS and fixed with 10% formalin overnight. After several PBS washes, cells were treated with 20 ⁇ g/ml proteinase K in 20mM Tris/HCI, pH 8 for 30min at 37DC, rinsed four times with PBS and air-dried.
  • the TUNEL reaction was performed using the apoptosis kit according to the manufacturer's instructions (Boehringer Mannheim, UK). Stained cells were illuminated at 488nm and fluoresced at 520nm.
  • the TUNEL stain which enzymatically adds tagged deoxyribonucleotides to blunt- ended DNA fragments, identified nucleic acid fragmentation characteristic of apoptosis.
  • LDS Iron accumulation in dermal fibroblasts in LDS may induce the production of collagen leading to the fibrotic skin changes observed and this may be through lipid peroxidation products.
  • One of the hallmarks of LDS is the progressive replacement of the subcutaneous adipose layer by fibrotic tissue.
  • septal cells in the subcutaneous fat layer showed haemosiderin accumulation by Perls' Prussian blue staining and we have previously demonstrated that these cells are actively expressing procollagen mRNA. This suggests that iron may also play a role in collagen production by subcutaneous adipose cells as in haemochromatosis.
  • Iron at higher concentrations than those used to induce collagen caused a decrease in dermal fibroblast cell viability, possibly due to the stimulation of apoptosis.
  • Ischaemia/reperfusion which has been suggested to occur in legs subjected to venous insufficiency, may exaggerate the effects of iron by acting as an inducer of stress.
  • Ferrous iron release from ferritin occurs in the presence of superoxide generated by xanthine oxidase system on reperfusion or partial ischaemia. Free iron generated in this manner would enhance the formation of toxic hydroxyl radicals leading to the perpetuation of tissue damage.
  • Inflammatory cells initially phagocytose these, however with continued extravasation these cells become overloaded and excess iron is then taken up by dermal fibroblasts.
  • Accumulation of low levels of iron in dermal fibroblasts in skin subjected to chronic venous insufficiency leads to the production of lipid peroxidation by-products and the development of fibrotic skin changes.
  • the build-up of iron to high levels in dermal fibroblasts results in cell death and eventual ulcer formation. These events are likely to be through the production of free radicals and enhanced by ischaemia/reperfusion.
  • the presence of iron-loaded LDS skin around a venous ulcer will perpetuate the fibrotic process so preventing ulcer healing and may lead to more extensive tissue damage and an increase ulcer size.
  • a gel ointment suitable for application to intact skin for the prevention or treatment of LDS is prepared according to the following formulation (percentages are by weight of the composition) :-
  • the ointment may be applied to intact skin of a patient exhibiting symptoms of venous insufficiency or LDS, or of an asymptomatic patient as a preventative treatment.
  • the ointment may be applied at least once a day in an effective amount.

Abstract

The invention provides the use of an iron chelating agent for the preparation of a composition for use in the prevention or treatment of lipodermatosclerosis by topical application to the lower leg.

Description

TREATMENT AND PREVENTION OF LIPODERMATOSCLEROSIS
The present invention relates to the use of iron scavenging compounds for the preparation of compositions for use in the treatment and prevention of lipodermatosclerosis.
In the United Kingdom, 10-20% of the adult population is affected by the complications of venous disease, including deep vein thrombosis, varicose veins, lipodermatosclerosis and venous ulceration. Approximately 50% of all venous ulcers are present for periods greater than nine months and two-thirds are recurrent. Venous problems are not only limited to the elderly, since greater than 40% of patients form venous ulcers before the age of 50. Venous disease consumes approximately 2% of the total annual healthcare budget in the UK.
In patients with venous disease, the valves in the veins of the lower limb become incompetent, generally due to deep vein thrombosis and/or superficial vein incompetence, resulting in venous hypertension on exercise and the retrograde flow of blood through the superficial venous system (venous reflux) to the blood vessels in the skin. Chronic venous disease often progresses from defective valves and the appearance of varicose veins, to the development of skin changes in the lower leg and finally to the formation of venous ulcers. Despite the frequency of venous disease, surprisingly little is understood of the mechanisms by which chronic venous hypertension leads to venous ulceration.
Many patients with venous insufficiency develop skin changes in the lower leg known as lipodermatosclerosis (LDS). LDS is also known as hypodermitis sclerodermaformis, liposclerosis, hypodermatosclerosis sclerodermoformis, lipomembranous change in chronic panniculitis and sclerosing panniculitis. LDS skin is characterised by skin induration or thickening and brown pigmentation caused by haemosiderin deposition. These features often occur in skin before ulceration as well as in skin surrounding an ulcer. The degree of skin thickening (induration or fibrosis) is thought to be directly related to venous ulcer formation and subsequently delayed healing. Removal of the fibrotic LDS skin surrounding venous ulcers by debridement often leads to increased ulcer healing. Treatment of this problem has for many years relied on established principles of compression and limb elevation and drug treatment has been of little benefit. Yet there is clearly a role for drugs in the management of venous disease either alone or in combination with compression therapy. It is likely to be beneficial to intervene in the initial processes that cause the lipodermatosclerotic skin changes leading to ulceration rather than to modify the repair processes when an ulcer has formed. The same processes that caused the ulcer are likely to contribute to its perpetuation and delayed healing.
The present invention relates to the inhibition of the effects of excess iron deposition in the skin following chronic venous insufficiency. The present inventors have found that excess iron may have a much larger influence on the early stages of lipodermatosclerosis than previously thought.
During venous insufficiency, repeated damage of cutaneous blood vessels due to venous hypertension, causes the leakage of blood proteins and erythrocytes. The damaged erythrocytes deposited in the interstitial tissue are thought to be cleared by dermal macrophages and the iron derived from haemoglobin stored within the cells as ferritin and in haemosiderin granules.
Ackerman et al., in 1988 performed x-ray spectrometry, a method based on x-ray fluorescence analysis, for non-invasive determination of iron levels in the skin of sixteen patients with venous ulceration. The mean (± SEM) iron concentration in the skin around the venous ulcer was elevated, compared with control values of nonulcerated skin (250±54 vs 128±39μg) and compared with normal skin from the forearm (250±54 vs 14±2.5μg). This group suggested that dermal iron deposition may not be an incidental by-product of increased venous pressure, but may actively perpetuate tissue damage in venous ulcerations. However, attempts to treat venous ulcers with inhibitors of the effects of excess iron have not been overly effective. The present inventors have found that there is little evidence of haemosiderin deposition in ulcer base tissue. It is thought that elevated levels of iron in ulcer wound fluid may be due to iron leaching into the wound fluid, father than to iron accumulation in the ulcer tissue itself.
It is known that dissolved iron in high concentrations is cytotoxic because the iron catalyses the formation of oxygen free radicals. The present inventors have found that even quite low concentrations of iron below the threshold for cytotoxicity can cause increased collagen production which may explain the fibrotic skin changes seen in LDS. It therefore seems that low levels of dissolved iron play an important part in the early stages of venous disease, in particular the fibrotic stages of lipodermatosclerosis. It further appears that removal or sequestering of dissolved iron could be an effective method to prevent or treat the fibrotic symptoms of lipodermatosclerosis.
In a first aspect the present invention provides the use of an iron chelating agent for the preparation of a composition for use in the prevention of lipodermatosclerosis by topical application to the lower leg.
In a second aspect the present invention provides the use of an iron chelating agent for the preparation of a composition for use in the treatment of lipodermatosclerosis by topical application to the lower leg.
The term "chelating agent" refers to a chemical moiety that functions as a bidentate or multidentate ligand for dissolved iron. Chelating agents which may be used herein should be safe for topical application and should exhibit a sufficiently high binding coefficient with dissolved iron to lower the concentration of dissolved iron in vivo and should neutralise the fibrotic effect of the iron when the iron is bound thereto. The chelating agent should also be capable of penetrating into the skin following topical application. By "safe" is meant chelating agents which may be used topically, at typical usage levels for extended periods of time, without causing any significant adverse skin reactions or other side effects.
The chelating agents useful in the present invention may be classified according to their donor groups; see The Design and Synthesis of Chelating Agents", Development of Iron Chelators for Clinical Use, Martell, Anderson and Badman, eds., Elsevier North Holland, Inc., New York, N.Y. (1981), pp. 67-104, which is hereby incorporated by reference. Because some chelating agents have more than one type of donor group, they may fall into more than one of the classes defined in this reference.
Preferably, the chelating agent is selected from the group consisting of aromatic amines, carbonyls, oximates, amines, carboxylates, alkoxides, enolates, phenoxides, catecholates, hydroxy acids, hydroxamates, ketoenolates, mercaptides, hydroxy aromatic amines, aromatic hydroxy acids, and mixtures thereof
Preferably, the chelating agent is selected from the group consisting of aromatic amines, carbonyls, oximates, enolates, phenoxides, catecholates and hydroxylates, and mixtures thereof.
Aromatic amine chelating agents preferably are selected from the group consisting of: 2,2'-dipyridylamine; 1 ,10-phenanthroline {o-phenanthroline}; di-2-pyridyl ketone; 2,3-bis(2-pyridyl) pyrazine; 2,3-bis(2-pyridyl)-5,6-dihydropyrazine; 1 ,1 '- carbonyldiimidazole; 2,4-bis(5,6-diphenyl-1 ,2,4-triazine-3-yl)pyridine; 2,4,6-tri(2- pyridyl)-1 ,3,5-triazine; 4,4'-dimethyl-2,2'-dipyridyl; 2,2'-biquinoline; di-2-pyridyl glyoxal {2,2'-pyridil}; 2-(2-pyridyl)benzimidazole; 2,2'-bipyrazine; 3-(2-pyridyl )5,6- diphenyl-1 ,2,4-triazine; 3-(4-phenyl-2-pyridyl)-5-phenyl-1 ,2,4-triazine; 3-(4-phenyl- 2-pyridyl)-5,6-diphenyl-1 ,2,4-triazine; 2,3,5,6-tetrakis-(2'-pyridyl)-pyrazine; 2,6- pyridinedicarboxylic acid; 2,4,5-trihydroxypyrimidine; phenyl 2-pyridyl ketoxime; 3- amino-5,6-dimethyl-1 ,2,4-triazine; 6-hydroxy-2-phenyl-3(2H)-pyridazinone; 2,4- pteridinediol {lumazine}; 2,2-'dipyridyl; and 2,3-dihydroxypyridine.
More preferably the aromatic amine chelating agent is selected from the group consisting of: di-2-pyridyl ketone; 1 ,1 '-carbonyldiimidazole and 2,2'-pyridil.
Oximate chelating agents preferably are selected from the group consisting of: 2- furildioxime; phenyl 2-pyridyl ketoxime; and 1 ,2-cyclohexanedione dioxime. In other preferred embodiments the chelating agent is selected from the group consisting of: ethylenediamine-N,N-bis-(2-hydroxyphenylacetic acid) dimethyl ester; diethyldithiocarbamic acid; 1-pyrrolidinecarbodithioic acid; and 3-amino-5,6- dimethyl-1 ,2,4-triazine.
Carboxy chelating agents preferably are selected from the group consisting of: 2,3-dihydroxybenzoic acid; 3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridine- carboxylic acid {pyridoxic acid}; ethylenediamine-N,N-bis-(2-hydroxyphenylacetic acid) dimethyl ester; and 2,6-pyridinedicarboxylic acid.
In other preferred embodiments the chelating agent is selected from the group consisting of: 5-hydroxy-2-(hydroxymethyl)-4H-pyran-4-one {kojic acid} and pyridoxic acid.
In other preferred embodiments the chelating agent is selected from the group consisting of: 1 ,2-dimethyl-3-hydroxypyrid-4-one; 3-hydroxy-2-methyl-4-pyrone; kojic acid; 1-hydroxy-4-methyl-6-(2,4,4-trimethylpentyl)-2(1H)-pyridone {piroctone olamine-Octopirox}; and 6-cyclohexyI-1 -hydroxy-4-methyl-2(1 H)-pyridinone {Ciclopirox}.
In other preferred embodiments the chelating agent is selected from the group consisting of: Octopirox; 6-hydroxy-2-phenyl-3(2H)-pyridazinone; Ciclopirox; 2,3- dihydroxybenzoic acid; 4,5-dihydroxy-1,3-benzene-disulfonic acid {Tiron}; ethylenediamine-N,N-bis-(2-hydroxyphenylacetic acid) dimethyl ester; pyridoxic acid; 2,3-dihydroxypyridine; 2,4,5-trihydroxypyrimidine; and 2,3- dihydroxynaphthalene.
In other preferred embodiments the chelating agent is selected from the group consisting of: 2,3-dihydroxynaphthalene; 2,4,5-trihydroxypyrimidine; kojic acid; 2,3- dihydroxypyridine; 3-hydroxy-2-methyl-4-pyrone; Tiron; 2,3-dihydroxybenzoic acid; 4-(2-amino-1-hydroxyethyl)-1 ,2-benzenediol; Ciclopirox; and Octopirox. In other preferred embodiments the chelating agent is selected from the group consisting of: 2,3-dihydroxybenzoic acid; and pyridoxic acid.
In other preferred embodiments the chelating agent is selected from the group consisting of: N-benzoyl -N-phenyl-hydroxylamine; desferrioxamine B {Desferal}; Ciclopirox; and Octopirox.
In other preferred embodiments the chelating agent is selected from the group consisting of: kojic acid.
In other preferred embodiments the chelating agent is selected from the group consisting of: diethyldithiocarbamic acid; and 1-pyrrolidinecarbodithioic acid.
Preferred chelating agents useful in the present invention which fall within the class of hydroxy aromatic amines include the following: 5,7-dichloro-8- hydroxyquinoline.
In other preferred embodiments the chelating agent is selected from the group consisting of: 2,3-dihydroxybenzoic acid; pyridoxic acid; and 2,6- pyridinedicarboxylic acid.
In other preferred embodiments the chelating agent is selected from the group consisting of: 2,2'-dipyridylamine; o-phenanthroline; di-2-pyridyl ketone; 2- furildioxime; 2,3-bis(2-pyridyl) pyrazine; Octopirox; 2,3-dihydroxybenzoic acid; ethylenediamine-N,N-bis-(2-hydroxyphenylacetic acid), dimethyl ester; 1,1'- carbonyldiimidazole; 1 ,2-dimethyl-3-hydroxypyrid-4-one; 2,4,6-tri(2-pyridyl)-1 ,3,5- triazine; 1-pyrrolidinecarbodithioic acid; diethyldithiocarbamic acid; Ciclopirox; 2,2'- dipyridyl; 1 ,2-cyclohexanedione dioxime; 3-hydroxy-2-methyl-4-pyrone; 2,3-bis(2- pyridyl)-5,6-dihydropyrazine; 3-(4-phenyl-2-pyridyl)-5-phenyl-1 ,2,4-triazine; kojic acid; 2,3-dihydroxypyridine; 2,2'-biquinoline; 2,2'-bipyrazine; 3-(2-pyridyl)-5,6- diphenyl-1 ,2,4-triazine; 4-(2-amino-1-hydroxyethyl)-1 ,2-benzenediol; and 4,4'- dimethyl-2,2'-dipyridyl. In other preferred embodiments the chelating agent is selected from the group consisting of: 2,2'-dipyridylamine; o-phenanthroline, di-2-pyridyl ketone; 2- furildioxime; 2,3-bis(2-pyridyl) pyrazine; Octopirox; 2,3-dihydroxybenzoic acid; ethylenediamine-N,N-bis-(2-hydroxyphenylacetic acid), dimethyl ester; 1 ,1'- carbonyldiimidazole; 1 ,2-dimethyl-3-hydroxypyrid-4-one; 2,4,6-tri(2-pyridyl)-1 ,3,5- triazine; 1-pyrrolidinecarbodithioic acid; diethyldithiocarbamic acid; and Ciclopirox. More preferred still chelating agents for use in the compositions and methods of the present invention including the following: 2,2'-dipyridylamine; o-phenanthroline, di-2-pyridyl ketone; 2-furildioxime; 2,3-bis(2-pyridyl) pyrazine; Octopirox; 2,3- dihydroxybenzoic acid; and ethylenediamine-N,N-bis-(2-hydroxyphenylacetic acid), dimethyl ester.
In other preferred embodiments the chelating agent is selected from the group consisting of: 2,2'-dipyridylamine; o-phenanthroline; di-2-pyridyl ketone; and 2- furildioxime.
Preferably, the chelating agent has a binding coefficient with aqueous Fe3+ of at least 106, preferably at least 109 and more preferably at least 1012. The binding coefficient is defined as the equilibrium constant for the reaction Fe3+ + Ln' → FeL(3-n)+
Preferably, the chelating agent is present in the composition at a concentration by weight of from about 1% to about 10%, preferably from about 2% to about 5%, of the composition.
The preferred chelating agents listed hereinabove are generally commercially available from one or more of the following suppliers: Aldrich Chemical Company, Milwaukee, Wis.; G.F.S. Chemicals, Columbus, Ohio; Dojindo Laboratories, Kumamoto, Japan; Sigma Chemical Company, St. Louis, Mo.; Ciba-Geigy, Summit, N.J.; Strem Chemicals, Newburyport, Mass.; and American Hoechst Corp., Summerville, N.J. A method for synthesizing 1 ,2-dimethyl-3-hydroxypyrid-4- one is disclosed in Kontoghiorghes, G. J., "L1--1 ,2-dimethyl-3-hydroxypyrid-4- one", Drugs of the Future, Vol. 13, No. 5 (1988), pp. 413-415, which is hereby incorporated by reference.
In addition to the active agent, the compositions used in the present invention contain a safe and effective amount of an acceptable carrier. The term "acceptable topical carrier" encompasses both pharmaceutically-acceptable carriers and cosmetically-acceptable carriers, and it encompasses substantially nonirritating compatible components (either taken alone or in mixtures) which are suitable for delivering the active component to the skin. The term "compatible", as used herein, means that the components of the carrier must be capable of being commingled with the chelating agent, and with each other, in a manner such that there is no interaction which would substantially reduce the efficacy of the composition during use for protecting the skin from the effects of UV radiation. These carriers must, of course, be of sufficiently high purity and sufficiently low toxicity to render them suitable for chronic topical administration to the skin of humans or lower animals. The term "safe and effective amount" of carrier means an amount sufficient to deliver the chelating agent to the skin but not so much as to cause any side effects or skin reactions, generally from about 50% to about 99%, preferably from about 90% to about 98%, of the composition.
The composition made in the present invention may be of any conventional topical application type. These include, for example, lotions, creams, gels, sticks, sprays, ointments, pastes, mousses and cosmetics. These product types may comprise either of two basic types of carrier systems, i.e., solutions and emulsions. The compositions formulated as solutions typically include a pharmaceutically- or cosmetically-acceptable organic solvent. The most typical example of such a solvent is water. Examples of other suitable organic solvents include: propylene glycol, polyethylene glycol (200-600), polypropylene glycol (425-2025), glycerol, 1 ,2,4-butanetriol, sorbitol esters, 1 ,2,6-hexanetriol, ethanol, isopropanol, butanediol, and mixtures thereof. These solutions contain from about 1% to about 20%, preferably from about 2% to about 10%, of the chelating agent, and from about 80% to about 99%, preferably from about 90% to about 98%, of an acceptable organic solvent. Emollients may be included in the carrier system of the present invention formulated as a solution. Such compositions contain from about 1% to about 20% of the chelating agent and from about 2% to about 50% of a pharmaceutically/cosmetically-acceptable emollient. As used herein, "emollients" refer to materials used for the prevention or relief of dryness, as well as for the protection of the skin. A wide variety of suitable emollients are known and may be used herein. Sagatin, Cosmetics, Science and Technology, 2nd Edition, Vol. 1 , pp. 32-43 (1972), incorporated herein by reference, contains numerous examples of suitable materials.
Lotions typically comprise from about 1 % to about 20%, preferably from about 2% to about 10%, of the chelating agent; from about 1% to about 20%, preferably from about 5% to about 10%, of an emollient; and from about 50% to about 90%, preferably from about 60% to about 80%, water. Another type of product that may be formulated from a solution carrier system is a cream. A cream of the present invention would comprise from about 1% to about 20%, preferably from about 2% to about 10%, of the chelating agent; from about 5% to about 50%, preferably from about 10% to about 20%, of an emollient, and from about 45% to about 85%, preferably from about 50% to about 75%, water. Yet another type of product that may be formulated from a solution carrier system is an ointment. An ointment may comprise a simple base of animal or vegetable oils or semi-solid hydrocarbons (oleaginous). Ointments may also comprise absorption ointment bases which absorb water to form emulsions. Examples of such ointment bases include, anhydrous lanolin and hydrophilic petrolatum. Emulsion ointment bases may be oil-in-water or water-in-oil emulsions. Ointment carriers may also be water soluble. Examples of such ointment carriers include glycol ethers, propylene glycols, polyoxyl stearates, and polysorbates. An ointment may also comprise from about 2% to about 10% of an emollient plus from about 0.1% to about 2% of a thickening agent. Examples of suitable thickening agents include: cellulose derivatives (e.g., methyl cellulose and hydroxy propylmethyl cellulose), synthetic high molecular weight polymers (e.g., carboxyvinyl polymer and polyvinyl alcohol), plant hydrocolloids (e.g., karaya gum and tragacanth gum), clay thickeners (e.g., colloidal magnesium aliminum silicate and bentonite), and carboxyvinyl polymers (Carbopols®)
If the carrier is formulated as an emulsion, from about 1% to about 10%, preferably from about 2% to about 5%, of the carrier system comprises an emulsifier. Emulsifiers may be nonionic, anionic or cationic. Preferred emulsifiers are anionic or nonionic, although the other types may also be used. Single emulsion skin care preparations, such as lotions and creams, of the oil-in- water type and water-in-oil type are well-known in the cosmetic art and are useful in the present invention.
Lotions and creams can be formulated as emulsions as well as solutions. Typically such lotions comprise from about 1 % to about 20%, preferably from about 2% to about 10%, of the chelating agent; from about 1% to about 20%, preferably from about 5% to about 10%, of an emollient; from about 25% to about 75%, preferably from about 45% to about 95%, water; and from about 1% to about 10%, preferably from about 2% to about 5%, of an emulsifier. Such creams would typically comprise from about 1% to about 20%, preferably from about 2% to about 10%, of the chelating agent; from about 1% to about 20%, preferably from about 5% to about 10%, of an emollient; from about 20% to about 80%, preferably from about 30% to about 70%, water; and from about 1% to about 10%, preferably from about 2% to about 5%, of an emulsifier. If the compositions are formulated as a gel or a cosmetic stick, a suitable amount of a thickening agent, as disclosed supra, is added to a cream or lotion formulation. The compositions may also be formulated as makeup products such as foundations, thereby enabling the compositions also to cover up the discoloration symptoms of lipodermatosclerosis. Foundations are solution or lotion-based with appropriate amounts of thickeners, pigments and fragrance.
The compositions may also include a safe and effective amount of a penetration enhancing agent. By "safe and effective amount" is meant an amount sufficient to enhance penetration of the chelating agent into the skin but not so much as to cause any side effects or skin reactions, generally from about 1% to about 5% of the composition. Examples of useful penetration enhancers, among others, are disclosed in US-A-4,537,776, US-A-4,552,872, US-A-4,557,934, US-A-4,130,667, US-A-3,989,816, US-A-4,017,641 , EP-A-0043738, US-A-4,537,776, US-A- 4,557,934 and US-A-4,130,667.
The compositions may comprise, in addition to the chelating agent, a safe and effective amount of a radical scavenging compound. By "safe and effective amount" is meant an amount sufficient to inhibit the deleterious effects of iron catalysed free radical formation when the composition is properly applied, but not so much as to cause any side effects or adverse skin reactions. The use of the radical scavenger tocopherol sorbate in the present invention in combination with the chelating agent is preferred. From about 1% to about 5% of these radical scavenging compounds may generally be used in the present invention in combination with the levels of chelating agent taught herein. Exact amounts will vary depending on which particular compound is used as these compounds vary somewhat in potency.
Preferably, the treatment or prevention comprises daily topical application for a period of at least three weeks.
Preferably, the patient is suffering from a venous disease or venous insufficiency. Preferably this is still at an early stage, for example the patient may have varicose veins but still little or no LDS.
Typically a safe and effective amount is from about 0.001 mg to about 1.0 mg, preferably from about 0.01 mg to about 0.5 mg, more preferably from about 0.05 mg to about 0.1 mg of the chelating agent per cm2 skin. The chelating agent may be simply spread or sprayed onto the skin or may preferably be rubbed into the skin to enhance penetration. For protection against chronic damage, application of the chelating agent several times daily; generally from about 2 times to about 5 times, preferably 2 times daily is preferred. Preferably, application of the chelating agent is continued daily for as long as the underlying venous insufficiency persists. EXPERIMENTAL
The current study addressed the hypothesis that excess iron deposited in skin subjected to chronic venous insufficiency is phagocytosed by dermal cells and at low levels causes enhanced collagen deposition leading to fibrotic skin changes but when in excess it mediates cell death and subsequent ulceration. The initial aims of the study were to assess the level and distribution of iron in the lower leg skin of patients with progressive venous disease. Histological and ultrastructural analysis of LDS skin biopsies showed that dermal fibroblasts as well as inflammatory cells contained iron in the form of ferritin and haemosiderin. The effects of increasing levels of iron on dermal fibroblast collagen production and cell viability were determined in vitro. Results suggest that iron at low concentrations causes increased collagen production but higher concentrations induces a significant decrease in cell viability which is likely to be due to iron induced apoptosis.
1. Experimental Study of the Concentration and Distribution of Iron in LDS Skin
Patient selection and sample collection
Patients undergoing varicose vein stripping were initially assessed by colour duplex ultrasonography and photoplethysmography to determine the cause and extent of venous disease, and then separated into two groups according to the International Society for Cardiovascular Surgery/Society for Vascular Surgery CEAP (clinical, etiologic, anatomic and pathologic) classification. Patients in class 3 CEAP (n=10) demonstrated varicose veins and oedema with no detectable skin changes on physical examination whereas CEAP class 4 patients (n=12) presented with trophic skin changes ascribed to lipodermatosclerosis, including skin thickening and hyperpigmentation. Control patients, CEAP class 0 (n=12), undergoing coronary artery by-pass surgery, demonstrated no clinical signs of venous disease when assessed. Patients with a history or clinical evidence of coexistent arterial disease, diabetes mellitus, connective tissue disease or medication known to affect collagen metabolism, were excluded from the study. Furthermore patients that had a previous healed ulcer were excluded. The average age (in years) and sex distribution (male :female) of the patients in each class was as follows; Class 0 CEAP 59± 6, 11 :1; Class 3 CEAP 39± 6, 1 :9; Class 4 CEAP 41 ± 14, 6:6 respectively.
Full-thickness excisional skin biopsies (4mm) were removed from above the medial malleolus of distal leg in the three patient groups. The Royal Free and University College London Medical School Ethics committee gave ethical approval for this study and all subjects provided informed written consent. Skin samples were immediately fixed in 4% paraformaldehyde in phosphate buffered saline (PBS) pH 7.4, overnight before being processed for wax histology. Tissue sections (5μm) were obtained from wax embedded samples and stained with Haemotoxylin and eosin and Perls' Prussian blue to assess tissue architecture and the distribution of haemosiderin respectively.
Immunocytochemistry
Inflammatory cells, including as macrophages, mast cells, neutrophils and lymphocytes, were identified by indirect immunocytochemistry. Sections were dewaxed, rehydrated, and treated with 0.3% H202 in PBS for 20min to block endogenous peroxidase activity followed by blocking serum corresponding the host of the secondary antibody. Sections were incubated with well-characterised primary antibodies for 1hr at room temperature in a humidified chamber. Monoclonal primary antibodies were raised against human macrophage, CD68 (1 :100 dilution; Dako, Cambridge, UK), neutrophil, CD15s (1:50 dilution; Serotec Ltd, Oxford, UK), mast cell tryptase (1 : 100 dilution; Serotec Ltd, Oxford, UK) and T-lymphocyte, CD3 (1:50 dilution, Serotec Ltd, Oxford, UK). Following three washes with PBS, the sections were incubated with biotinyiated-conjugated secondary antisera against mouse or rat IgG (1 :300 dilution; Dako, Cambridge, UK), for 1hr at room temperature. Sections were washed three times with PBS prior to incubation with streptavidin-conjugated horseradish peroxidase (1:100 dilution; Dako, Cambridge, UK) for 30min. Peroxidase activity was visualised with chromogen diaminobenzidine substrate (FAST DAB, Sigma, Poole, UK) and sections were counterstained with 1% eosin and mounted. Control sections were incubated with either normal blocking serum or mouse/rat lgG1 instead of primary antisera. For dual localisation, sections were initially assessed for inflammatory cells by immunoperoxidation and counterstained with Perls' Prussian blue for haemosiderin.
Ultrastructural analysis
Three additional LDS and normal skin samples were fixed in a solution of 1% paraformaldehyde and 5% glutaraldehyde in 100mM sodium cacodylate buffer, pH 7.4 at room temperature overnight, and post-fixed in 1% osmium tetroxide in 0.1 M sodium cacodylate buffer, pH 7.4 for 1 hr. Specimens were washed, stained with an aqueous saturated solution of uranyl acetate for 1 hr, dehydrated and embedded in araldite epoxy resin. Semi-thin sections (0.5-1 μm) were cut on a Reichert microtome, stained with 1% toluidine blue and examined under a Zeiss Axiophot light microscope equipped with phase contrast optics. Ultra-thin sections (70-1 OOnm) were collected on copper grids, stained with uranyl acetate and lead citrate and viewed in a Philips 400 transmission electron microscope (Eindhoven, Holland).
Results
The presence and distribution of iron was assessed in skin biopsies from patients with progressive stages of venous disease by Perls' Prussian blue staining. Red blood cell extravasation and iron in the form of haemosiderin was observed in all LDS samples examined whereas it was absent in skin samples from patients with venous insufficiency but without clinical evidence of LDS and normal control skin. In LDS, haemosiderin was deposited throughout the dermis, in both a cellular and extracellular distribution. In addition, it was clearly found in the few remaining septal cells of the fibrotic subcutaneous layer. Dual localisation of inflammatory cells and haemosiderin demonstrated that macrophages, mast cells and neutrophils contained iron deposits. However, there was also an abundance of Perls staining in elongated cells aligned along collagen fibres which was not associated with brown DAB localisation of inflammatory cells. This suggests that a non-inflammatory cell type may also take up excess iron in LDS. Ultrastructural analysis of LDS samples confirmed that macrophages and neutrophils contained clusters of electron dense iron particles recognised as ferritin and haemosiderin laden siderosomes. Furthermore, cells within the collagen fibres were identified as dermal fibroblasts and found to contain similar deposits of iron
2. Experimental Study of the effect of iron on dermal fibroblast collagen production
Experimental Approach
Adult human dermal fibroblasts were isolated from normal dermal skin by explant culture and were grown in DMEM medium supplemented with penicillin (100U/ml), streptomycin (100μg/ml) and L-glutamine (2mM), containing 10% FCS at 37DC, in a humidified, 5% C02 atmosphere. Cells were characterised using well- characterised antibodies against specific markers and were used at passage 7 to 9.
Primary dermal fibroblasts were plated at 105 cells/ml in DMEM with 10% FCS in a 12 well plate. At confluence, cells were washed twice with PBS and loaded with iron according to a modified method of Ruiz et al. (2000). Briefly, serum-free DMEM incubation media containing 50μM ascorbate as a reducing agent, 200μM proline, 250μM citric acid as a carrier with and without 10-100μM iron chloride was added to the cells. After 24hr, ascorbate at 200μM final was re-added to the media and the cultures incubated for a further 24hr before being processed for collagen analysis (n=6) and cell proliferation (n=4). Positive controls contained TGF-β1 at 1ng/ml instead of iron chloride. Cell layer and media proteins were precipitated with 67% ethanol at 4DC and samples filtered to separate proteins from free amino acids and small peptides prior to drying. Protein samples were hydrolysed with 6M HCI. Hydroxyproline levels were measured as an index of procollagen synthesis using a reverse-phase HPLC method developed in our laboratory. Cell proliferation was assessed by counting viable cells following trypsinisation. Collagen production was expressed as the amount of hydroxyproline per 105 cells.
Preliminary data suggest that iron causes an increase in collagen production after 48hours.
Experiment 3: The effect of iron on dermal fibroblast viability in culture.
Fibroblast viability assay Primary dermal fibroblasts were plated in 96-well plates at 105 cells/ ml in 100μl media supplemented with 0.4% FCS. Intact cells are relatively impermeable to iron therefore iron was loaded using the iron-chelating fungistat 8-hydroxyquinoline
(8HQ). 8HQ chelates with iron and rapidly transfers the metal across the intact plasma membrane of cells. After 24 hrs, cells were washed twice with PBS and loaded with 100μl serum-free DMEM containing stoichiometric quantities of ferric chloride and ferric ammonium citrate (to prevent precipitation of insoluble iron hydroxides) with 8-hydroxyquinonine (8-HQ) used as a carrier at concentrations of 1-100μM in a method modified from Jacob AK, Hotchkiss RS, DeMeester SL, Hiramatsu M, Karl IE, Swanson PE, Cobb JP, Buchman TG. Surgery 122:243-53 (1997). Control experiments added iron without 8-HQ carrier and 8-HQ without iron. In addition, the membrane-impermeable iron chelator, deferoxamine (DFX; Sigma) at 200μM was added to prevent the uptake of iron by the cells. Previous studies have shown that iron loading is complete after 30min (Jacob et al., 1997), therefore 30 min incubation with iron was used in all experiments. Viable cells accumulate the vital dye, neutral red, in their lysosomes and so neutral red (0.003%) in 100μl serum-free media was applied to washed cells and incubated for a further 2 hr. Excess dye was aspirated, the cells were washed with phosphate buffered saline, pH 7.4 (PBS), and lysed with 100μl 50% ethanol containing 1% acetic acid. Absorbency was measured at 560nm and viability calculated as a fraction of control cell absorbency after blank absorbency was deducted.
Apoptosis assays
To determine the cause of cell death, TUNEL assay for apoptosis was used. For TUNEL staining, cells were grown on glass Labtek slides and when semi-confluent rinsed with PBS and fixed with 10% formalin overnight. After several PBS washes, cells were treated with 20μg/ml proteinase K in 20mM Tris/HCI, pH 8 for 30min at 37DC, rinsed four times with PBS and air-dried. The TUNEL reaction was performed using the apoptosis kit according to the manufacturer's instructions (Boehringer Mannheim, UK). Stained cells were illuminated at 488nm and fluoresced at 520nm.
To assess the effect of iron on dermal fibroblast viability, the uptake of neutral red dye following incubation with iron was analysed. Dermal fibroblasts did not absorb ferric iron from the media unless iron was complexed to 8-HQ. Iron with the carrier (8HQ) significantly decreased dermal fibroblast viability from μM which reached a plateau at higher concentrations (>25μM). Concentrations of iron below 1 μM did not produce a significant decrease in cell viability over serum free controls. Iron added in combination with the iron chelator (DFX) completely abrogated this effect at all concentrations of iron tested. However, iron or carrier alone had no significant effect on dermal fibroblast viability.
The TUNEL stain, which enzymatically adds tagged deoxyribonucleotides to blunt- ended DNA fragments, identified nucleic acid fragmentation characteristic of apoptosis. Cells loaded with iron and carrier, 8-HQ, were TUNEL positive compared with untreated control cells.
Discussion In the current study, the amount and distribution of iron in LDS was investigated. It was demonstrated for the first time that dermal fibroblasts contain iron in the form of ferritin and haemosiderin in addition to inflammatory cells. It is likely that inflammatory cells are unable to accommodate the continuous deposition of iron from extravasated erythrocytes and redistribution into mesenchymal cells takes place. The effect of iron on dermal fibroblast function is thought to be to stimulate collagen deposition. Iron is known to act in the stabilisation of procollagen by acting as a cofactor in the hydroxylation of lysine and proline residues. The current study showed that a low concentration of iron caused an increase in collagen production by dermal fibroblasts.
Iron accumulation in dermal fibroblasts in LDS may induce the production of collagen leading to the fibrotic skin changes observed and this may be through lipid peroxidation products. One of the hallmarks of LDS is the progressive replacement of the subcutaneous adipose layer by fibrotic tissue. In the current study, septal cells in the subcutaneous fat layer showed haemosiderin accumulation by Perls' Prussian blue staining and we have previously demonstrated that these cells are actively expressing procollagen mRNA. This suggests that iron may also play a role in collagen production by subcutaneous adipose cells as in haemochromatosis.
Iron at higher concentrations than those used to induce collagen caused a decrease in dermal fibroblast cell viability, possibly due to the stimulation of apoptosis.
Ischaemia/reperfusion, which has been suggested to occur in legs subjected to venous insufficiency, may exaggerate the effects of iron by acting as an inducer of stress. Ferrous iron release from ferritin occurs in the presence of superoxide generated by xanthine oxidase system on reperfusion or partial ischaemia. Free iron generated in this manner would enhance the formation of toxic hydroxyl radicals leading to the perpetuation of tissue damage. Based on these findings a new hypothesis of venous ulceration is postulated. Chronic venous insufficiency in the lower leg causes leakage of erythrocytes from cutaneous blood vessels into the interstitial tissue. Inflammatory cells initially phagocytose these, however with continued extravasation these cells become overloaded and excess iron is then taken up by dermal fibroblasts. Accumulation of low levels of iron in dermal fibroblasts in skin subjected to chronic venous insufficiency leads to the production of lipid peroxidation by-products and the development of fibrotic skin changes. However, the build-up of iron to high levels in dermal fibroblasts results in cell death and eventual ulcer formation. These events are likely to be through the production of free radicals and enhanced by ischaemia/reperfusion. The presence of iron-loaded LDS skin around a venous ulcer will perpetuate the fibrotic process so preventing ulcer healing and may lead to more extensive tissue damage and an increase ulcer size.
Treatment of this problem has for many years relied on established principles of compression and limb elevation and no drug treatment has been shown to be more effective. Yet there is clearly a role for drugs in the management of venous disease either alone or in combination with compression therapy. It is likely to be beneficial to intervene in the initial processes that cause the lipodermatosclerotic skin changes leading to ulceration rather than to modify the repair processes when an ulcer has formed. The same processes that caused the ulcer are likely to contribute to its perpetuation and delayed healing. The free radical scavengers, topical allopurinol or dimethyl sulfoxide, were given to 88 ulcer patients, on a 3 months, double blind controlled study and showed a significant increase in healing (Salim A.S. The role of oxygen derived free radicals in the management of venous (varicose) ulceration: a new approach. World J. Surg. 15, 264-269 (1991)).
We have found that there is little evidence of haemosiderin in ulcer base tissue, although others have found raised iron levels in chronic wound fluid suggesting that much of the iron leaks out of the wound. Therefore, it is logical to address the problem of iron overload by applying iron chelators topically to pre-ulcerated skin.
EXAMPLES
A gel ointment suitable for application to intact skin for the prevention or treatment of LDS is prepared according to the following formulation (percentages are by weight of the composition) :-
Carboxymethylcellulose 2.4%
Hydroxyethylcellulose 0.3%
Sodium chloride 0.24%
Propylene glycol 20.2% o-phenanthroline 2.0% Water balance
The ointment may be applied to intact skin of a patient exhibiting symptoms of venous insufficiency or LDS, or of an asymptomatic patient as a preventative treatment. The ointment may be applied at least once a day in an effective amount.
Many other embodiments falling within the scope of the accompanying claims will be apparent to the skilled reader.

Claims

1. Use of an iron chelator for the preparation of a composition for use in the prevention of lipodermatosclerosis by topical application to the lower leg.
2. Use of an iron chelator for the preparation of a composition for use in the treatment of lipodermatosclerosis by topical application to the lower leg.
3. Use according to claim 1 or 2, wherein the chelating agent is selected from the group consisting of aromatic amines, carbonyls, oximates, amines, carboxylates, alkoxides, enolates, phenoxides, catecholates, hydroxy acids, hydroxamates, ketoenolates, mercaptides, hydroxy aromatic amines, aromatic hydroxy acids, and mixtures thereof
4. Use according to claim 3, wherein the chelating agent is selected from the group consisting of aromatic amines, carbonyls, oximates, enolates, phenoxides, catecholates and hydroxylates, and mixtures thereof.
5. Use according to claim 1 or 2, wherein the chelating agent is selected from the group consisting of: 2,2'-dipyridylamine; 1 ,10-phenanthroline {o- phenanthroline}; di-2-pyridyl ketone; 2,3-bis(2-pyridyl) pyrazine; 2,3-bis(2-pyridyl)- 5,6-dihydropyrazine; 1 ,1 '-carbonyldiimidazole; 2,4-bis(5,6-diphenyl-1 ,2,4-triazine- 3-yl)pyridine; 2,4,6-tri(2-pyridyl)-1 ,3,5-triazine; 4,4'-dimethyl-2,2'-dipyridyl; 2,2'- biquinoline; di-2-pyridyl glyoxal {2,2'-pyridil}; 2-(2-pyridyl)benzimidazole; 2,2'- bipyrazine; 3-(2-pyridyl )5,6-diphenyl-1 ,2,4-triazine; 3-(4-phenyl-2-pyridyl)-5- phenyM ,2,4-triazine; 3-(4-phenyl-2-pyridyl)-5,6-diphenyl-1 ,2,4-triazine; 2,3,5,6- tetrakis-(2'-pyridyl)-pyrazine; 2,6-pyridinedicarboxylic acid; 2,4,5- trihydroxypyrimidine; phenyl 2-pyridyl ketoxime; 3-amino-5,6-dimethyl-1 ,2,4- triazine; 6-hydroxy-2-phenyl-3(2H)-pyridazinone; 2,4-pteridinediol {lumazine}; 2,2- 'dipyridyl; and 2,3-dihydroxypyridine.
6. Use according to claim 1 or 2, wherein the chelating agent is selected from the group consisting of: di-2-pyridyl ketone; 1,1 '-carbonyldiimidazole and 2,2'- pyridil.
7. Use according to claim 1 or 2, wherein the chelating agent is selected from the group consisting of: 2-furildioxime; phenyl 2-pyridyl ketoxime; and 1 ,2- cyclohexanedione dioxime.
8. Use according to claim 1 or 2, wherein the chelating agent is selected from the group consisting of: ethylenediamine-N,N-bis-(2-hydroxyphenylacetic acid) dimethyl ester; diethyldithiocarbamic acid; 1-pyrrolidinecarbodithioic acid; and 3- amino-5,6-dimethyl-1 ,2,4-triazine.
9. Use according to claim 3, wherein the chelating agent is selected from the group consisting of: 2,3-dihydroxybenzoic acid; 3-hydroxy-5-(hydroxymethyl)-2- methyl-4-pyridine-carboxylic acid {pyridoxic acid}; ethylenediamine-N,N-bis-(2- hydroxyphenylacetic acid) dimethyl ester; and 2,6-pyridinedicarboxylic acid.
10. Use according to claim 1 or 2, wherein the chelating agent is selected from the group consisting of: 5-hydroxy-2-(hydroxymethyl)-4H-pyran-4-one {kojic acid} and pyridoxic acid.
11. Use according to claim 1 or 2, wherein the chelating agent is selected from the group consisting of: 1 ,2-dimethyl-3-hydroxypyrid-4-one; 3-hydroxy-2-methyl-4- pyrone; kojic acid; 1-hydroxy-4-methyl-6-(2,4,4-trimethylpentyl)-2(1 H)-pyridone {piroctone olamine-Octopirox}; and 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)- pyridinone {Ciclopirox}.
12. Use according to claim 1 or 2, wherein the chelating agent is selected from the group consisting of: Octopirox; 6-hydroxy-2-phenyl-3(2H)-pyridazinone;
Ciclopirox; 2,3-dihydroxybenzoic acid; 4,5-dihydroxy-1,3-benzene-disulfonic acid {Tiron}; ethylenediamine-N,N-bis-(2-hydroxyphenylacetic acid) dimethyl ester; pyridoxic acid; 2,3-dihydroxypyridine; 2,4,5-trihydroxypyrimidine; and 2,3- dihydroxynaphthalene.
13. Use according to claim 1 or 2, wherein the chelating agent is selected from the group consisting of: 2,3-dihydroxynaphthalene; 2,4,5-trihydroxypyrimidine; kojic acid; 2,3-dihydroxypyridine; 3-hydroxy-2-methyl-4-pyrone; Tiron; 2,3- dihydroxybenzoic acid; 4-(2-amino-1-hydroxyethyl)-1 ,2-benzenediol; Ciclopirox; and Octopirox.
14. Use according to claim 1 or 2, wherein the chelating agent is selected from the group consisting of: 2,3-dihydroxybenzoic acid; and pyridoxic acid.
15. Use according to claim 1 or 2, wherein the chelating agent is selected from the group consisting of: N-benzoyl -N-phenyl-hydroxylamine; desferrioxamine B {Desferal}; Ciclopirox; and Octopirox.
16. Use according to claim 1 or 2, wherein the chelating agent is selected from the group consisting of: kojic acid.
17. Use according to claim 1 or 2, wherein the chelating agent is selected from the group consisting ofg: diethyldithiocarbamic acid; and 1 -pyrrolidinecarbodithioic acid. Other preferred chelating agents are analogs, homologs and isomers of the above mercaptides which exhibit at least about 50% inhibition of iron-catalyzed hydroxyl radical formation in the in vitro solution radical assay or at least about a 20% reduction in skin wrinkle grade in the in vivo mouse skin wrinkling test. Preferred chelating agents useful in the present invention which fall within the class of hydroxy aromatic amines include the following: 5,7-dichloro-8- hydroxyquinoline.
18. Use according to claim 1 or 2, wherein the chelating agent is selected from the group consisting of: 2,3-dihydroxybenzoic acid; pyridoxic acid; and 2,6- pyridinedicarboxylic acid.
19. Use according to claim 1 or 2, wherein the chelating agent is selected from the group consisting of: 2,2'-dipyridylamine; o-phenanthroline; di-2-pyridyl ketone; 2-furildioxime; 2,3-bis(2-pyridyl) pyrazine; Octopirox; 2,3-dihydroxybenzoic acid; ethylenediamine-N,N-bis-(2-hydroxyphenylacetic acid), dimethyl ester; 1 ,1'- carbonyldiimidazole; 1 ,2-dimethyl-3-hydroxypyrid-4-one; 2,4,6-tri(2-pyridyl)-1 ,3,5- triazine; 1-pyrrolidinecarbodithioic acid; diethyldithiocarbamic acid; Ciclopirox; 2,2'- dipyridyl; 1 ,2-cyclohexanedione dioxime; 3-hydroxy-2-methyl-4-pyrone; 2,3-bis{2- pyridyl)-5,6-dihydropyrazine; 3-(4-phenyl-2-pyridyl)-5-phenyl-1 ,2,4-triazine; kojic acid; 2,3-dihydroxypyridine; 2,2'-biquinoline; 2,2'-bipyrazine; 3-(2-pyridyl)-5,6- diphenyl-1 ,2,4-triazine; 4-(2-amino-1-hydroxyethyl)-1 ,2-benzenediol; and 4,4'- dimethyl-2,2'-dipyridyl.
20. Use according to claim 1 or 2, wherein the chelating agent is selected from the group consisting of: 2,2'-dipyridylamine; o-phenanthroline, di-2-pyridyl ketone;
2-furildioxime; 2,3-bis(2-pyridyl) pyrazine; Octopirox; 2,3-dihydroxybenzoic acid; ethylenediamine-N,N-bis-(2-hydroxyphenylacetic acid), dimethyl ester; 1 ,1'- carbonyldiimidazole; 1 ,2-dimethyl-3-hydroxypyrid-4-one; 2,4,6-tri(2-pyridyl)-1 ,3,5- triazine; 1-pyrrolidinecarbodithioic acid; diethyldithiocarbamic acid; and Ciclopirox. More preferred still chelating agents for use in the compositions and methods of the present invention including the following: 2,2'-dipyridylamine; o-phenanthroline, di-2-pyridyl ketone; 2-furildioxime; 2,3-bis(2-pyridyl) pyrazine; Octopirox; 2,3- dihydroxybenzoic acid; and ethylenediamine-N,N-bis-(2-hydroxyphenylacetic acid), dimethyl ester.
21. Use according to claim 1 or 2, wherein the chelating agent is selected from the group consisting of: 2,2'-dipyridylamine; o-phenanthroline; di-2-pyridyl ketone; and 2-furildioxime.
22. Use according to claim 1 or 2, wherein the chelating agent has a binding coefficient with aqueous Fe3+ of at least 106.
23. Use according to any preceding claim, wherein the chelating agent is present in the composition at a concentration by weight of from about 1% to about 10%, preferably from about 2% to about 5%, of the composition.
24. Use according to any preceding claim, wherein the treatment or prevention comprises daily topical application for a period of at least three weeks.
25. Use according to any preceding claim, wherein the patient is suffering from a venous disease.
26. Use according to claim 25, wherein the patient has varicose veins.
PCT/GB2002/002955 2001-06-27 2002-06-26 Treatment and prevention of lipodermatosclerosis WO2003002119A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0115707.2 2001-06-27
GB0115707A GB2376886A (en) 2001-06-27 2001-06-27 Treatment and prevention of lipodermatosclerosis

Publications (1)

Publication Number Publication Date
WO2003002119A1 true WO2003002119A1 (en) 2003-01-09

Family

ID=9917447

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/002955 WO2003002119A1 (en) 2001-06-27 2002-06-26 Treatment and prevention of lipodermatosclerosis

Country Status (2)

Country Link
GB (1) GB2376886A (en)
WO (1) WO2003002119A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008035152A1 (en) * 2006-09-18 2008-03-27 Carlo Ghisalberti Cosmetic method to remove the dark undereye marks
WO2009125295A2 (en) * 2008-04-08 2009-10-15 Systagenix Wound Management Ip Co.B.V. Genetic markers of wound development
WO2009125296A2 (en) * 2008-04-08 2009-10-15 Systagenix Wound Management Ip Co. B.V. Genetic markers of wound development
EP2493483A2 (en) * 2009-10-28 2012-09-05 B. Eugene Guthery Rosacea topical skin treatment method and formulation

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20021080A1 (en) * 2002-05-21 2003-11-21 Marcello Izzo PHARMACEUTICAL ASSOCIATIONS FOR TOPICAL USE BASED ON CHELATES OF THE METAL PROTEASIS FERROINHIBITORS AND FACTOR XIII FOR THE TREATMENT OF
WO2005082386A2 (en) * 2004-02-20 2005-09-09 Human Matrix Sciences, Llc Manganese and iron based compounds for elastogenesis and connective tissue treatment
WO2006033732A1 (en) 2004-08-17 2006-03-30 Invitrogen Corporation Synthesis of highly luminescent colloidal particles
US7566693B2 (en) 2005-02-22 2009-07-28 Human Matrix Sciences, Llc Elastin protective polyphenolics and methods of using the same
US8114829B2 (en) 2005-02-22 2012-02-14 Human Matrix Sciences, Llc Elastin protective polyphenolics and methods of using the same
US8642578B2 (en) 2005-03-29 2014-02-04 Human Matrix Sciences, Llc Elastin protective polyphenolics and methods of using the same
JP5249919B2 (en) 2006-03-29 2013-07-31 エフ．ホフマン−ラ ロシュ アーゲー Pyridine and pyrimidine derivatives as mGluR2 antagonists

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7302M (en) * 1966-03-04 1969-09-29

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7302M (en) * 1966-03-04 1969-09-29

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KONTOGHIORGHES G J: "Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs.", TOXICOLOGY LETTERS. NETHERLANDS OCT 1995, vol. 80, no. 1-3, October 1995 (1995-10-01), pages 1 - 18, XP000986910, ISSN: 0378-4274 *
REINHAREZ D: "[Pigmentation following sclerosis]. Les pigmentations apres sclerose.", PHLEBOLOGIE, (1983 OCT-DEC) 36 (4) 337-44, XP001095988 *
THIBAULT P.K. ET AL: "Correlation of serum ferritin levels and postsclerotherapy pigmentation: A prospective study.", JOURNAL OF DERMATOLOGIC SURGERY AND ONCOLOGY, (1994) 20/10 (684-686)., XP001105706 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008035152A1 (en) * 2006-09-18 2008-03-27 Carlo Ghisalberti Cosmetic method to remove the dark undereye marks
WO2009125295A2 (en) * 2008-04-08 2009-10-15 Systagenix Wound Management Ip Co.B.V. Genetic markers of wound development
WO2009125296A2 (en) * 2008-04-08 2009-10-15 Systagenix Wound Management Ip Co. B.V. Genetic markers of wound development
WO2009125295A3 (en) * 2008-04-08 2009-12-17 Systagenix Wound Management Ip Co.B.V. Genetic markers of mmp- 12 gene for wound development
WO2009125296A3 (en) * 2008-04-08 2010-03-25 Systagenix Wound Management Ip Co. B.V. Genetic markers of wound development
EP2493483A2 (en) * 2009-10-28 2012-09-05 B. Eugene Guthery Rosacea topical skin treatment method and formulation
EP2493483A4 (en) * 2009-10-28 2013-07-17 B Eugene Guthery Rosacea topical skin treatment method and formulation

Also Published As

Publication number Publication date
GB0115707D0 (en) 2001-08-22
GB2376886A (en) 2002-12-31

Similar Documents

Publication Publication Date Title
Wenk et al. Selective pick-up of increased iron by deferoxamine-coupled cellulose abrogates the iron-driven induction of matrix-degrading metalloproteinase 1 and lipid peroxidation in human dermal fibroblasts in vitro: a new dressing concept
Aviram et al. Pomegranate juice consumption inhibits serum angiotensin converting enzyme activity and reduces systolic blood pressure
Fitzpatrick et al. Endothelium-dependent vascular effects of Pycnogenol
Bae et al. (−) Epigallocatechin gallate hampers collagen destruction and collagenase activation in ultraviolet-B-irradiated human dermal fibroblasts: involvement of mitogen-activated protein kinase
Petrassi et al. Pycnogenol® in chronic venous insufficiency
WO2003002119A1 (en) Treatment and prevention of lipodermatosclerosis
Tanaka et al. High dose vitamin C counteracts the negative interstitial fluid hydrostatic pressure and early edema generation in thermally injured rats
US6242010B1 (en) Synergistic antioxidant compositions in management of hemorrhoids and other ano-rectal inflammatory conditions
EP1392328B1 (en) Medicament for protection in radiotherapy
JPH09278663A (en) Regulation of reactivity of human blood platelet by peroral administration of extract from maritime pine (pycnogenol (r))
Glowinski et al. Generation of reactive oxygen metabolites by the varicose vein wall
AU2012200390B2 (en) Treatment and/or prevention of inflammation and cutaneous photodamage and photoprotection of the skin with a water-soluble extract from plant of solanum genus
Kandemir et al. Effects of oral administrations of pomegranate seed extract on surgical wound healing in rabbits
EA001870B1 (en) Method of prophylaxis and protection of blood vessels from restenosis (variants), methods of treatment and prophylaxis of various forms of hypertension, atherosclerosis (variants)
JP6026540B2 (en) Composition for the treatment of peripheral ulcers of various causes
KR100816774B1 (en) Cosmetic composition for preventing or improving skin diseases
Fischer et al. Effects of antihistamines on phorbol ester tumor promotion and vascular permeability changes
JPH03255033A (en) Treating agent for trichophyton
CN102821773B (en) Composition for treating, preventing or relieving macular degeneration, containing vaccinium uliginosum extract or vaccinium uliginosum fractions as active ingredient
KR102450000B1 (en) A composition for postprandial anti-hyperglycemia comprising coffee extract
Hyun et al. Aster koraiensis extract improves impaired skin wound healing during hyperglycemia
Shimoda et al. Effect of antioxidants, anti-inflammatory drugs, and histamine antagonists on sparfloxacin-induced phototoxicity in mice
Han et al. Preservation of Human Saphenous Vein against Reactive Oxygen Species‐induced Oxidative Stress by Green Tea Polyphenol Pretreatment
Upaganlawar et al. Effect of vitamin E and green tea on hemodynamic, electrocardiographic and some biochemical alterations in experimentally induced myocardial infarction in rats
Mergiaw et al. Effects of Thymus schimperi and Moringa stenopetala leaf extracts on lipid peroxidation and total antioxidant status in pre-eclampsia rat models

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP